Skip Navigation
Search Menu
Find an Expert

 


Christine Lee Hann, M.D., Ph.D.

Photo of Dr. Christine Lee Hann, M.D., Ph.D.

Assistant Professor of Oncology

Female

Expertise: Lung Cancer, Medical Oncology

Research Interests: New drug development for lung cancer; Small cell and non-small cell lung cancer

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map

Background

Titles

  • Assistant Professor of Oncology

Education

Degrees

  • MD PhD; Biochemistry and Molecular Biology, Thomas Jefferson University (2000)

Residencies

  • The University of Chicago / Internal Medicine (2002)

Fellowships

  • Johns Hopkins University School of Medicine / Hematology and Oncology (2007)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (2006)

Research & Publications

Clinical Trial Keywords

lung cancer

Selected Publications

Research Summary:

Dr. Hann is a member of the Upper Aerodigestive Cancer Program, with a primary focus on developing novel therapeutics for lung cancer, particularly small cell lung cancer. As a post-doctoral fellow, her research focused on the preclinical evaluation of a novel small molecule inhibitor which is currently in Phase I/II clinical trials.

She is the recipient of several awards, including an ASCO Young Investigator Award and a FAMRI Young Clinical Scientist Award.

As a faculty member, she sees patients with non-small cell and small cell lung cancer and conducts innovative research with both basic biological and major clinical implications.

Current research projects in the lab include: 1) an evaluation of mechanisms of resistance to a small molecule inhibitor of Bcl-2 currently in clinical trials, 2) a preclinical evaluation of a novel anthracycline in a primary xenograft model of small cell lung cancer, and 3) the development of a small cell lung cancer-specific nanoparticle delivery system for gene therapy.

Trainees in Dr. Hanns lab learn basic molecular biology techniques and approaches to preclinical evaluation of various therapeutic approaches to small cell lung cancer treatment.

Journal Citations:

Hann, C.L.; Brahmer, J.R. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Current treatment options in oncology. 2007 Feb;8(1):28-37.

Hann, C.L.; Rudin, C.M. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in molecular medicine. 2007 Apr;13(4):150-157.

Hann, C.L.; Streiff, M.B. Vena caval filters. In: Kitchens, C.S.; Alving, B.M.; Kessler, C.M., editors. 2nd ed, Consultative Hemostasis and Thrombosis. Philadelphia: Elsevier Press; 2007. p. 531-552.

Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; Rudin, C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-2328.

Hann, C.L.; Rudin, C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008 Nov 30;22(13):1486-1492; discussion 1493-1486, 1498-1500, 1506.

Rudin, C.M.; Hann, C.L.; Peacock, C.D.; Watkins, D.N. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):315-322.

Streiff, M.B.; Hann, C.L. Chapter 12: Inferior Vena Cava Ineterruption. In: Ginsberg, editor, Evidence-Based Hematology: British Medical Journal Publishing Group; 2008.

Gallia, G.L.; Tyler, B.M.; Hann, C.L.; Siu, I.M.; Giranda, V.L.; Vescovi, A.L.; Brem, H.; Riggins, G.J. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Molecular cancer therapeutics. 2009 Feb;8(2):386-393.

Holdhoff, M.; Supko, J.G.; Gallia, G.L.; Hann, C.L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2009 Sep 19;97(2):241-250.

Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; LoRusso, P.M.; Von Hoff, D.D.; de Sauvage, F.J.; Low, J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009 Sep 17;361(12):1173-1178.

Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.

Yauch, R.L.; Dijkgraaf, G.J.; Alicke, B.; Januario, T.; Ahn, C.P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C.A.; Tang, T.; Bazan, J.F.; Kan, Z.; Seshagiri, S.; Hann, C.L.; Gould, S.E.; Low, J.A.; Rudin, C.M.; de Sauvage, F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009 Oct 23;326(5952):572-574.

Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.

Holdhoff, M.; Supko, J.G.; Gallia, G.L.; Hann, C.L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2010 Apr;97(2):241-245.

Activities & Honors

Honors

  • Young Clinical Scientist Award, Flight Attendant Medical Research Institute, 2007
  • Pearl M. Stetler Fellowship Award for Women Physicians, Johns Hopkins University, 2006
  • Young Investigator Award, American Society of Clinical Oncology, 2005

Memberships

  • American Association for Cancer Research
  • American Society of Clinical Oncology

Videos & Media

Meet Christine Hann, M.D., Ph.D.

Is this you? Edit Profile